Adoption of MRL for Ectosan Vet in Norway

RNS Number : 4109F

Benchmark Holdings PLC

15 July 2021

 

15 July 2021

Benchmark Holdings plc

("Benchmark", the "Company" or the "Group")

Adoption of MRL for Ectosan ^â Vet in Norway

Benchmark Holdings, the aquaculture biotechnology company, is pleased to announce that the MRL (Maximum Residue Limit) for Ectosan^â Vet has been adopted into the Agreement of the European Economic Area (the EEA Agreement); and today, has entered into Norwegian legislation completing the regulatory steps required for the commercialisation of Ectosan^â Vet and CleanTreat^â in Norway.

Trond Williksen,   CEO, commented:

"With the granting of the Marketing Authorisation on 2^nd July, the MRL ratified by the European Commission and now in Norwegian legislation, we have completed the regulatory steps required to begin the commercialisation of Ectosan ^â Vet and CleanTreat ^â in Norway."   

"We are excited to bring this much needed solution to the salmon industry, driving sustainability through improved animal welfare and yield while protecting the environment. " 

Enquiries

Benchmark Holdings plc	Tel: [phone]
Trond Williksen, CEO Septima Maguire, CFO Ivonne Cantu, Investor Relations Director
Numis (Broker and NOMAD)	Tel: [phone]
James Black / Freddie Barnfield / Duncan Monteith
MHP
Katie Hunt /Alistair de Kare-Silver / Charlie Protheroe	Tel: [phone]                          [e-mail]

 

END

 

 

MSCEADXSFDNFEFA